[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201790650A1 - DOSAGE FORM AND METHODS OF APPLICATION OF ABIRATERONE ACETATE - Google Patents

DOSAGE FORM AND METHODS OF APPLICATION OF ABIRATERONE ACETATE

Info

Publication number
EA201790650A1
EA201790650A1 EA201790650A EA201790650A EA201790650A1 EA 201790650 A1 EA201790650 A1 EA 201790650A1 EA 201790650 A EA201790650 A EA 201790650A EA 201790650 A EA201790650 A EA 201790650A EA 201790650 A1 EA201790650 A1 EA 201790650A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
application
abiraterone acetate
dosage form
compositions
Prior art date
Application number
EA201790650A
Other languages
Russian (ru)
Inventor
Маура Мерфи
Пол Немет
Х. Уилльям Бош
Мэттью Каллахан
Сатя Бхамидипати
Джейсон Коулмен
Кристофер Хилл
Марк Норрет
Original Assignee
Айсьютика Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201790650(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/707,922 external-priority patent/US20150246060A1/en
Application filed by Айсьютика Инк. filed Critical Айсьютика Инк.
Publication of EA201790650A1 publication Critical patent/EA201790650A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)

Abstract

Описаны фармацевтические композиции, включая дозированные лекарственные формы, содержащие абиратерона ацетат, и способы получения таких композиций.Pharmaceutical compositions are described, including dosage forms containing abiraterone acetate, and methods for making such compositions.

EA201790650A 2014-09-18 2015-09-18 DOSAGE FORM AND METHODS OF APPLICATION OF ABIRATERONE ACETATE EA201790650A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052294P 2014-09-18 2014-09-18
US14/707,922 US20150246060A1 (en) 2013-03-15 2015-05-08 Abiraterone Acetate Formulation and Methods of Use
PCT/US2015/050889 WO2016044701A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use

Publications (1)

Publication Number Publication Date
EA201790650A1 true EA201790650A1 (en) 2017-07-31

Family

ID=55533897

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790650A EA201790650A1 (en) 2014-09-18 2015-09-18 DOSAGE FORM AND METHODS OF APPLICATION OF ABIRATERONE ACETATE

Country Status (17)

Country Link
EP (1) EP3193857A4 (en)
JP (1) JP2017528457A (en)
KR (2) KR102491439B1 (en)
CN (1) CN106687112A (en)
AP (1) AP2017009804A0 (en)
AU (1) AU2015317466A1 (en)
BR (1) BR112017003219A2 (en)
CA (1) CA2958316A1 (en)
CO (1) CO2017002472A2 (en)
EA (1) EA201790650A1 (en)
IL (1) IL250270B (en)
MD (1) MD20170048A2 (en)
MX (1) MX2017003525A (en)
PH (1) PH12017500239A1 (en)
SG (1) SG11201701139YA (en)
TN (2) TN2018000318A1 (en)
WO (1) WO2016044701A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016162229A1 (en) 2015-04-10 2016-10-13 Capsugel Belgium N.V. Abiraterone acetate lipid formulations
EP3606506A4 (en) * 2017-04-07 2021-01-06 MAA Laboratories, Inc. PROCESS FOR IMPROVING THE SOLUBILITY AND BIOAVAILABILITY OF THERAPEUTICS
EP3914234A4 (en) * 2019-01-25 2022-09-14 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions
CA3131034A1 (en) 2019-03-06 2020-09-10 Matthew J. Sharp Abiraterone prodrugs
CN110742870B (en) * 2019-12-04 2021-04-20 武汉大学 Abiraterone acetate preparation and preparation method thereof
CN111110646A (en) * 2020-02-19 2020-05-08 纳兰迦(上海)生物医药科技有限公司 Prescription and preparation method of low-specification abiraterone acetate oral preparation
CN113384542B (en) * 2020-03-14 2024-03-29 鲁南制药集团股份有限公司 Tablet of steroid CYP17 inhibitor solid dispersion and preparation method thereof
BR112022021040A2 (en) * 2020-04-16 2022-12-06 Tavanta Therapeutics Hungary Incorporated METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER
TW202207925A (en) * 2020-05-08 2022-03-01 比利時商健生藥品公司 Treatments of prostate cancer with combinations of abiraterone acetate and niraparib
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
JP2024506382A (en) 2021-02-15 2024-02-13 プロペラ セラピューティクス インコーポレイテッド Abiraterone prodrug
KR20240044329A (en) 2022-09-28 2024-04-04 한미약품 주식회사 Oral composite tablet comprising abiraterone acetate and prednisolone
KR20240145412A (en) 2023-03-27 2024-10-07 한미약품 주식회사 Pharmaceutical formulation comprising abiraterone acetate and prednisolone and method for preparing same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105919939A (en) * 2009-04-24 2016-09-07 伊休蒂卡有限公司 Production of encapsulated nanoparticles at commercial scale
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
WO2014009434A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
CN102743393A (en) 2012-07-27 2012-10-24 海南盛科生命科学研究院 Medicinal composition containing abiraterone acetate and preparation technology thereof
KR102121404B1 (en) * 2013-03-15 2020-06-11 썬 파마 글로벌 에프제트이 Abiraterone acetate formulation

Also Published As

Publication number Publication date
TN2017000098A1 (en) 2018-10-19
EP3193857A4 (en) 2018-04-11
IL250270B (en) 2021-02-28
TN2018000318A1 (en) 2020-01-16
CN106687112A (en) 2017-05-17
MD20170048A2 (en) 2017-08-31
JP2017528457A (en) 2017-09-28
KR102491439B1 (en) 2023-01-25
MX2017003525A (en) 2017-06-21
KR102617537B1 (en) 2023-12-22
IL250270A0 (en) 2017-03-30
AP2017009804A0 (en) 2017-03-31
PH12017500239A1 (en) 2017-07-03
CO2017002472A2 (en) 2017-07-11
BR112017003219A2 (en) 2017-11-28
KR20170070025A (en) 2017-06-21
CA2958316A1 (en) 2016-03-24
SG11201701139YA (en) 2017-03-30
WO2016044701A1 (en) 2016-03-24
EP3193857A1 (en) 2017-07-26
AU2015317466A1 (en) 2017-02-23
KR20230014878A (en) 2023-01-30

Similar Documents

Publication Publication Date Title
EA201790650A1 (en) DOSAGE FORM AND METHODS OF APPLICATION OF ABIRATERONE ACETATE
IL272367A (en) Antibodies against CD39, compositions containing antibodies against CD39 and methods of using antibodies against CD39
EA201891083A1 (en) COMPOSITIONS OF ANTIBODIES TO CD38 FOR SCRAPTURE AND THEIR APPLICATION
DOP2017000078A (en) INDAZOLS REPLACED WITH BENCILO AS INHIBITORS OF BUB1.
MX2023008686A (en) Modulatory polynucleotides.
EA201891087A1 (en) RET INHIBITORS
LT3674298T (en) SUBSTITUTED INDAZOLES, METHOD OF THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE FOR THE PRODUCTION OF DRUGS
EA201691582A1 (en) NEW PHARMACEUTICAL PREPARATIONS
DK3236943T3 (en) COMPOSITIONS FOR ILEO-JEJUNAL DRUG ADMINISTRATION
EA201591728A1 (en) HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR APPLICATION
BR112016015706A2 (en) compound, use of it and pharmaceutical composition
EA201691945A1 (en) ANTIBODIES TO HEMAGGLUTININ VIRUS OF TYPE B VIRUS AND METHODS OF THEIR APPLICATION
DK3153169T3 (en) Method of treatment of tumor, pharmaceutical composition and medicine box set
EA202091397A1 (en) BENZOQUINOLONE VMAT2 INHIBITORS
LT3116491T (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICLY ACTIVE COMPOUNDS
MX373309B (en) ANTIBIOTIC COMPOSITIONS OF CEFTOLOZAN.
EA201791454A1 (en) DRUG FORMS FOR TRANSDERMAL ADMINISTRATION
TR201821116A2 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING POSACONAZOL AND THE MANUFACTURING METHOD
DK3672631T5 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA-AMYLOID ANTIBODIES
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
ZA201703467B (en) Methods of treating ocular conditions
EA201890364A1 (en) COMPOUNDS SUITABLE FOR INHIBITING ROR-GAMMA-t
CL2017000587A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
EA201792262A1 (en) PIROGLUTAMAT VORTIOKSETINA
IN2014CH00840A (en)